A recent outbreak of influenza in Hong Kong was caused by a highly virulent virus of avian origin. Concern that the appearance of such a virus in the human population may be a harbinger of a new pandemic has brought increased attention to the issue of antivirals available for treatment of influenza. A/HongKong/156/97 (H5N1), the first virus of H5N1 subtype isolated from a human host, is highly virulent in the mouse model and can infect mouse lungs without requiring adaptation. High mortality and evidence of systemic disease, including spread to the brain after intranasal inoculation, are observed. Zanamivir, a novel neuraminidase inhibitor, is effective at decreasing replication of the virus in vitro. In a model of lethal challenge in mice, zanamivir reduces lung titers of the virus and decreases morbidity and mortality.
of influenza virus (H1N1, H2N2, and H3N2) [4] . Because the introduction of these viruses into the human population represents a shift in the viral surface glycoproteins HA and neuraminidase (NA), the vaccines in use at the time of introduction would not be protective.
Antiviral drugs, such as amantadine and rimantadine, are effective in reducing morbidity and mortality from influenza and were used during the recent outbreak. The effectiveness of these antivirals, however, is limited by rapid emergence of drugresistant mutant strains of influenza virus and by adverse effects of the drugs themselves [5, 6] . A novel anti-influenza drug, zanamivir, has demonstrated efficacy against influenza virus infection in animals and in humans and is well-tolerated [7] [8] [9] . In humans, it is administered topically to the respiratory tract by intranasal spray and has proven effective in both prophylaxis against and treatment of experimentally induced influenza virus infection [7, 8] . In addition, there are no reports to date of selection of zanamivir-resistant mutants under clinical trial conditions. These features make zanamivir an attractive drug for the control of influenza and have led to interest in its use in situations such as the H5N1 outbreak in Hong Kong. However, despite the high potency of zanamivir against the NA of highly virulent avian influenza viruses, the drug has failed to protect chickens against systemic disease [10, 11] . It is therefore important to investigate whether zanamivir has efficacy against the strain responsible for the recent outbreak, A/HongKong/ 156/97 (H5N1). Here we describe characteristics of the virus in cell culture and our efforts to establish a model of infection in mice for A/HongKong/156/97 (H5N1).
Materials and Methods
Virus. Influenza virus A/HongKong/156/97 (H5N1) was cultured from a patient who died of influenza virus infection in May of 1997. The virus was initially isolated in MDCK cells. Virus stock was prepared from virus that had been passaged twice in mouse lungs and then propagated in embryonated chicken eggs. The egg ID 50 (EID 50 ) was calculated. Cell culture experiments were done using MDCK cells cultured in Eagle MEM containing 5% fetal calf serum. All experiments were done in a biosafety level 3 (BL-3ϩ) containment facility at St. Jude Children's Research Hospital.
Mice. Female BALB/c mice (Jackson Laboratory, Bar Harbor, ME) were maintained under specific pathogen-free conditions until they were used at 8-12 weeks of age.
Reagents. Zanamivir (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuramic acid) was obtained from Glaxo Wellcome Research and Development (Stevenage, UK) for use in this study.
Sequence analysis. RNA extraction from virus-containing material was performed in BL-3ϩ containment following manufacturer's instructions (RNAeasy kit; Qiagen, Chatsworth, CA). Reverse transcription and polymerase chain reaction (RT-PCR) amplification of genes of interest were done with standard methodologies. RT-PCR products were purified using QIAquick PCR purification kit (Qiagen), sequenced by Taq Dye Terminator chemistry according to manufacturer's instructions (Applied Biosystems, Foster City, CA), and then analyzed on an ABI 373 DNA sequencer.
NA inhibition assay. To establish the concentration of zanamivir that reduces NA activity by 50% (IC 50 ), NA inhibition assays were done with a method modified from that of Potier et al. [12] . Briefly, 25 mL of formalin-inactivated virus and 25 mL of a 10-fold dilution of zanamivir were preincubated for 30 min at room temperature. Next, a fluorescent sodium (4-methylumbelliferyl-a-D-Nacetylneuraminate) substrate was added to the reaction (final concentration, 50 mM). Reaction mixtures were incubated for 30 min at 37ЊC, at which time the reactions were stopped by addition of 150 mL of 14 mM NaOH solution in 83% ethanol. Fluorescence was determined with a Fluoroskan (Labsystems, Helsinki) spectrophotometer (excitation wavelength, 355 nm; emission wavelength, 460 nm).
Plaque reduction assay. A plaque reduction assay was done as described previously [13] . Briefly, ∼50 pfu of virus were adsorbed on MDCK cells for 1 h, after which cells were washed and overlaid with agar containing 10-fold dilutions of zanamivir in MEM. After 4 days of incubation, the agar overlay was discarded, and plaques were visualized by crystal violet staining to determine a plaque size used to calculate IC 50 .
Infection and drug administration in mice. The protocol used here for infection of mice with influenza virus has been described previously [14] . Briefly, mice were anesthetized by inhalation of metofane and were inoculated intranasally with 100 mL of a virus suspension. The viral challenge dose in all experiments contained 3 mouse LD 50 (MLD 50 ). Drug administration was done by intranasal inoculation in anesthetized mice to deliver the drug topically to the lungs, as has been described previously [15] . In treatment courses with zanamivir, drug administration was initiated 24 h after infection and continued twice daily for 5 days. In prophylaxis and treatment courses, drug was administered 24 h before infection, 4 h before infection, 4 h after infection, and then twice daily for 5 days beginning 24 h after infection. Daily assessments for weight and mortality were made on all mice. A mean survival day (MSD) was calculated by the formula [f(d Ϫ 1)]/N, where f is MSD ϭ S the number of mice recorded dead on day d (survivors on day 18 were included in f for that day) and N is the number of mice in a group [16] .
Virus titers in mice. Animals were infected with 3 MLD 50 of virus, mice were killed daily, and solid organs (brain, liver, kidney, spleen, heart, and lung) were removed under sterile conditions. Organs were collected in that order to avoid contamination with virus from the lungs. Blood specimens were obtained after removal of the brain. Titers of infectious virus recovered from the organs were measured by infecting MDCK cells with 10-fold dilutions of ground organs suspended in a total volume of 1 mL of MEM. After 1 h of virus adsorption at room temperature, cells were washed with fresh medium to remove unbound virus and any drug that may have been present in tissues, and new medium was supplied. After 3 days, the presence of virus was detected by a standard hemagglutination assay with a 0.5% suspension of turkey erythrocytes in PBS. Titers of infectious virus are presented as log 10 TCID 50 /1 mL.
Results
Preparation of virus stock. The influenza virus strain A/ HongKong/156/97 was initially isolated from a patient in MDCK cells. Because the mouse is not a natural host for influenza viruses [17] , the virus was then passaged in the lungs of mice via intranasal inoculation, sacrifice of the animals, and harvesting of their lungs to determine whether the mouse could be used as a mammalian model for infection. The virus did not require adaptation to mice and grew to high titers during the first passage. The virus was then propagated in embryonated chicken eggs to make a stock of the virus for experiments in cell culture and mice.
A/HongKong/156/97 in the mouse model. To determine virulence of the virus in a mouse model, groups of 9 animals were infected with 10-fold dilutions of the virus in sterile PBS starting with 10 4.8 EID 50 (10 4.6 pfu) per mouse. To estimate the mouse ID 50 (MID 50 ), 5 mice from each group were killed on day 3 after infection, and their lung homogenates were tested for virus in MDCK cells (table 1) . The virus grew readily and to high titers in mouse lungs. The MID 50 for A/HongKong/156/97 was ∼1 EID 50 (1.3 pfu).
Weight loss as a measure of morbidity of A/HongKong/156/ 97 correlated well with the dose of virus used to infect the mice (table 1) . The greatest weight loss was 24% on day 3 after infection in the group infected with the largest amount of virus, while only slight weight reduction was noted in the mice infected with 1 EID 50 and none in the groups infected with !1 EID 50 .
By day 11, all animals in the groups infected with ∼6 EID 50 and higher had died. All mice infected with a lower dose of virus lived at least 18 days, at which time the experiment was ended. An MLD 50 was estimated at ∼2 EID 50 , and the MSD correlated well with the infectious dose of virus given (table 1) . Therefore, we have established that A/HongKong/156/97 can infect mice and that this strain is highly virulent in this animal model. Because A/HongKong/156/97 causes systemic disease in chickens [1] , it was important to determine whether this strain produces disseminated infection in the mouse model. The tissue tropism of the virus was studied by determining the virus titer in solid organs. Twelve mice were infected with 3 MLD 50 of virus; then, either 1 or 2 mice were sacrificed on days 3-9. Virus was recovered from the lung consistently and at high titers (table 2) . Although virus could be recovered from all other solid organs, including the brain, the titers were low and inconsistent. Therefore, A/HongKong/156/97 has the potential to spread systemically, although the titers in other organs did not reach the high values found in lungs. However, it is important to note that this was an unadapted strain that had been passaged only twice in mice.
A second set of experiments was designed to address the question of systemic spread of the virus through the bloodstream by measuring virus titers in the lung, blood, and brain, after infection with A/HongKong/156/97 (H5N1) in groups of 8 mice. Two mice were sacrificed daily and their organs harvested. Virus was found in the blood at an average TCID 50 of 3.9 log 10 on day 3 after infection and 3.6 on day 6 after infection, an ∼3 log lower concentration than in the lungs, where the average TCID 50 was 6.2 log 10 on day 3 after infection and 6.5 on day 6 after infection. Virus was also found in brain at a further reduction of 1 to 2 logs, with an average TCID 50 of 2.6 on day 3 after infection and 1.3 on day 6 after infection. These experiments indicate that the virus can spread systemically through the bloodstream and can be found in brain tissue without prior adaptation to the mouse host, although not with the full virulence displayed in the lungs.
Studies to address the question of whether transmission from mouse to mouse can occur have been done, and no transmission has been observed under any clinical conditions tested thus far (data not shown).
Inhibition of A/HongKong/156/97 influenza virus by zanamivir in vitro.
Because zanamivir targets the NA enzyme activity that plays an important role in virus release from infected cells [18] , we first assessed the effect of the drug in vitro. In NA inhibition assays, the NA of A/HongKong/156/97 was highly sensitive to zanamivir, with an IC 50 of 1 nM (0.3 ng/mL). We then assessed the effect of zanamivir on virus release during replication by a plaque reduction assay on MDCK cell monolayers. The IC 50 for plaque size was 1 nM (0.3 ng/mL), and only "pinpoint" plaques were observed at 10 nM (3.0 ng/mL). This result demonstrates that A/HongKong/156/97 is more sensitive to the effects of zanamivir than are highly virulent chicken viruses studied previously [19] .
Inhibition of A/HongKong/156/97 influenza virus by zanamivir in the mouse model. We examined the effect of zanamivir on infection with A/HongKong/156/97 in the mouse model by determining virus titer in the lung, weight loss (a measure of morbidity), and MSD (a measure of mortality). To optimize our ability to detect differences between the infected and control groups, all mice were infected with 3 MLD 50 of the virus, the amount that led to the greatest increase in survivors after treatment in previous studies of antivirals [16] . Groups of mice received prophylaxis and treatment with either zanamivir (25 mg/ kg/day) or with water instilled intranasally. Prophylaxis and treatment with zanamivir reduced the virus titers in lungs by ∼2 logs compared with that in untreated mice (table 3). All mice in the control group had died by day 6 after infection, so no titer is available for that day. None of the zanamivir-treated mice died during the 18 days of observation.
To assess morbidity and mortality in a mouse model of zanamivir treatment, we first inoculated groups of mice and then intranasally administered either zanamivir (25 mg/kg) or sterile distilled water. Mice treated with zanamivir had a mean loss of 5% of their body weight on day 5 after infection and an MSD of 11.3. Mice in the control group had a mean loss of 14.1% of their body weight on day 5 after infection and an MSD of 7.9. In a second experiment, groups of 10 mice received prophylaxis and treatment with zanamivir (2.5 mg/kg or 25 mg/ kg) or sterile water. Mice receiving prophylaxis and treatment had a longer MSD and more survivors than did controls (table  4) . Mice receiving the lower dose of zanamivir had an MSD and number of survivors intermediate between the other 2 groups. These results demonstrate that zanamivir has efficacy against A/HongKong/156/97, reducing lung titers of the virus, morbidity, and mortality in this mouse model of infection.
Discussion
An outbreak of H5N1 influenza in Hong Kong during the winter of 1997-1998 has caused great interest in influenza virus A/HongKong/156/97 (H5N1) and in antivirals that might be used to prevent or ameliorate disease caused by it. The antivirals currently used for influenza, amantadine and rimantadine, are limited in their ability to effectively treat influenza by adverse effects and by the emergence of resistance during treatment [5, 6] . Vaccines are a powerful tool for prevention of disease but likely would be of little efficacy in a pandemic situation engendered by antigenic shift of the virus to a new subtype [4] . Because of these factors, the development and evaluation of new antivirals for the treatment of influenza have become priorities for the future of influenza research. In the present study, we establish the virulence of influenza virus A/ HongKong/156/97 (H5N1) in a mammalian animal model and demonstrate that zanamivir, an NA inhibitor, effectively protects against lethal challenge with the virus.
The mouse is not a natural host for influenza virus, and no avian viruses have been reported to infect and cause disease in the mouse before this report. Our results demonstrate that A/ HongKong/156/97 is highly virulent in the mouse model, infecting mouse lungs with an MID 50 nearly equal to the EID 50 for the virus. This strain required no adaptation to the host and caused severe morbidity and mortality. Although the infection was primarily pulmonary, we found evidence of systemic spread to solid organs, including the brain. A related avian virus, isolated from a chicken in Hong Kong during the human epidemic, A/chicken/HongKong/27403/97 (H5N1), also causes disease and kills mice without adaptation (unpublished data). These viruses appear to be unique in this respect among avian influenza viruses studied thus far.
Zanamivir was able to inhibit the activity of the NA and replication of the virus in vitro as measured by NA inhibition and plaque reduction assays. Our findings concur with those from previous studies in which the drug inhibited the NAs of highly pathogenic avian influenza viruses in vitro [11] . In our mammalian model of infection, zanamivir provided protection from lethal challenge compared with controls as measured by three indices: decrease in lung virus titers, decrease in morbidity as assessed by weight loss, and decrease in mortality, both absolutely by numbers surviving and by time between infection and death (MSD). However, it is important to point out that the data reported here are for prophylaxis and treatment of disease and may not reflect the outcome in the situation of delayed treatment.
An important characteristic of zanamivir is that emergence of drug-resistant mutants has not been a problem in the limited clinical and laboratory experience available. Such mutants have been isolated but are of doubtful significance clinically, in contrast to the situation with amantadine and rimantadine [20] . Virus isolated from zanamivir-treated mice at the end of therapy did not differ from stock virus in NA inhibition or plaque reduction assays, while parallel experiments with rimantadine demonstrated rapid emergence of drug-resistant mutants (unpublished data). This is an important observation, given the data reported here that although morbidity and mortality were reduced and lung virus titers were substantially lower in zanamivir-treated animals than in untreated controls, virus remained present in the lungs of mice throughout the course of the experiments. Further studies examining longer courses of treatment may be warranted.
In previous studies of zanamivir, the drug protected against lethal challenge in chickens with a fowl plague virus of subtype H7N7 but failed to protect against NA subtypes N1, N2, and N3 [11] . This is in direct contrast to our data reported here, in which zanamivir was protective against NA subtype N1 in a mammalian model. However, a much higher dose of virus (100 LD 50 ) was used in the protection experiment in chickens and may have a bearing on the apparent discrepancy. A/HongKong/ 156/97 is known to have a 15-aa deletion in the stalk region of the NA [3] . Previous studies of NA stalk lengths have established that this area is a factor in host range restriction and tissue tropism and may be involved in virulence of the virus in different hosts [21] . Although the series of basic amino acids at the cleavage site of the HA is likely the major virulence factor for this virus [1] [2] [3] , it is possible that the NA stalk deletion plays a role in host range of the virus and in its tissue tropism within a host. A restricted tissue tropism related to the stalk deletion may explain the minimal systemic spread observed in these experiments compared with the behavior of the virus in chickens. This may also explain why zanamivir, an NA inhibitor, has a protective effect against lethal challenge against this virus but not against other highly virulent avian viruses with an N1 subtype in chickens. Studies to address the role of the NA in host restriction and tissue tropism with this virus are underway at present.
